Pentixapharm Phase 3 financing and BUY rating

NuWays AG initiated and updated coverage of Pentixapharm Holding AG with a BUY rating and a target price of EUR 7.20, implying about 270% upside. The research highlights Pentixapharm's lead diagnostic asset PentixaFor, a PET/CT scan for subtyping primary aldosteronism (PA), a common cause of hypertension. In July 2025, the Pediatric Endocrine Society updated guidelines to recommend universal screening of hypertensive patients for PA, expanding the addressable patient pool. Pentixapharm completed a rights issuance raising approximately EUR 19.7 million net, with anchor shareholder Eckert Wagniskapital exercising its rights in full. The company now has pro forma cash of about EUR 25 million, extending its runway into early 2028 and funding the Phase 3 study (PANDA). PentixaFor has received FDA Fast Track and EMA PRIME designations. NuWays expects first patient enrollment in H2 2026 and potential commercial partnering in 2027. The research also notes Novartis reported Pluvicto sales up 43% year-over-year in Q2 2026, indicating growth in the radiopharma market.